Literature DB >> 28251500

Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales.

Dinesh Khanna1,2, Ron D Hays3,4, Andrew B Shreiner5, Gil Y Melmed6, Lin Chang7,8, Puja P Khanna9, Roger Bolus10,11, Cynthia Whitman11, Sylvia H Paz3,4, Tonya Hays3,4, Steven P Reise12, Brennan Spiegel13,14,15,16,17.   

Abstract

BACKGROUND: The NIH-sponsored Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal (GI) Symptoms scales were developed to assess patients' GI symptoms in clinical settings. AIMS: To assess responsiveness to change and provide minimally important difference (MID) estimates for the PROMIS GI Symptoms scales.
METHODS: A sample of 256 GI outpatients self-administered the eight PROMIS GI Symptoms scales (gastroesophageal reflux, disrupted swallowing, diarrhea, bowel incontinence/soilage, nausea and vomiting, constipation, belly pain, and gas/bloating/flatulence) at two visits. Patient self-reported and physician-reported assessments of the subjects' overall GI condition were employed as change anchors. In addition, we prospectively assessed change at both visits using a GI-symptom anchor, the Gastrointestinal Symptom Rating Scale (GSRS). Responsiveness to change was assessed using F-statistics. The minimally changed group was those somewhat better or somewhat worse on the retrospective anchors and changing by one category on the modified GSRS (e.g., from slight to mild discomfort to moderate to moderately severe discomfort).
RESULTS: Responsiveness to change was statistically significant for 6 of 8 PROMIS scales using the self-report GI anchor, 3 of 8 scales using the physician-reported anchor, and 5 of 5 scales using the corresponding GSRS scales as anchors. The MID estimates for scales for improvement and worsening were about 0.5-0.6 SD using the GSRS anchor and generally larger in magnitude than the change for the "about the same" group.
CONCLUSIONS: The responsiveness and MID estimates provided here for the PROMIS GI Symptoms scales can aid in scale score interpretation in clinical trials and observational studies.

Entities:  

Keywords:  Gastroenterology; Gastrointestinal disorders; PROMIS®; Patient-reported outcomes

Mesh:

Year:  2017        PMID: 28251500      PMCID: PMC5532518          DOI: 10.1007/s10620-017-4499-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  EQ-5D: a measure of health status from the EuroQol Group.

Authors:  R Rabin; F de Charro
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

2.  Defining clinically meaningful change in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2003-05       Impact factor: 6.437

Review 3.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Authors:  Dennis Revicki; Ron D Hays; David Cella; Jeff Sloan
Journal:  J Clin Epidemiol       Date:  2007-08-03       Impact factor: 6.437

4.  Items, Instruments, Crosswalks, and PROMIS.

Authors:  James F Fries; Eswar Krishnan; Bonnie Bruce
Journal:  J Rheumatol       Date:  2009-06       Impact factor: 4.666

Review 5.  Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases.

Authors:  James E Everhart; Constance E Ruhl
Journal:  Gastroenterology       Date:  2009-01-03       Impact factor: 22.682

Review 6.  Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database.

Authors:  Puja Khanna; Nikhil Agarwal; Dinesh Khanna; Ron D Hays; Lin Chang; Roger Bolus; Gil Melmed; Cynthia B Whitman; Robert M Kaplan; Rikke Ogawa; Bradley Snyder; Brennan Mr Spiegel
Journal:  Am J Gastroenterol       Date:  2013-12-17       Impact factor: 10.864

7.  Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Authors:  Dinesh Khanna; Daniel E Furst; Paul Maranian; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Terri Getzug; Ron D Hays
Journal:  J Rheumatol       Date:  2011-07-01       Impact factor: 4.666

8.  Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

Authors:  D A Revicki; M Wood; I Wiklund; J Crawley
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

9.  Depression and abdominal pain in IBS patients: the mediating role of catastrophizing.

Authors:  Jeffrey M Lackner; Brian M Quigley; Edward B Blanchard
Journal:  Psychosom Med       Date:  2004 May-Jun       Impact factor: 4.312

10.  Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales.

Authors:  Brennan M R Spiegel; Ron D Hays; Roger Bolus; Gil Y Melmed; Lin Chang; Cynthia Whitman; Puja P Khanna; Sylvia H Paz; Tonya Hays; Steve Reise; Dinesh Khanna
Journal:  Am J Gastroenterol       Date:  2014-09-09       Impact factor: 10.864

View more
  16 in total

1.  Measuring pelvic floor disorder symptoms using patient-reported instruments: proceedings of the consensus meeting of the pelvic floor consortium of the American Society of Colon and Rectal Surgeons, the International Continence Society, the American Urogynecologic Society, and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction.

Authors:  L G Bordeianou; J Anger; M Boutros; E Birnbaum; J C Carmichael; K Connell; E J B De; A Mellgren; K Staller; S A Vogler; M M Weinstein; F A Yafi; T Hull
Journal:  Tech Coloproctol       Date:  2019-12-11       Impact factor: 3.781

2.  Cohort Profile: The Christchurch IBS cOhort to investigate Mechanisms FOr gut Relief and improved Transit (COMFORT).

Authors:  Phoebe Heenan; Rob H Creemers; Shriya Sharma; Jacqueline Keenan; Simone Bayer; Wayne Young; Janine Cooney; Kelly Armstrong; Karl Fraser; Paula M Skidmore; Nicholas J Talley; Nicole Roy; Richard B Gearry
Journal:  Inflamm Intest Dis       Date:  2020-07-08

3.  Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Authors:  D M Evon; J Amador; P Stewart; B B Reeve; A S Lok; R K Sterling; A M Di Bisceglie; N Reau; M Serper; S Sarkar; J K Lim; C E Golin; M W Fried
Journal:  Aliment Pharmacol Ther       Date:  2018-01-29       Impact factor: 8.171

4.  "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C.

Authors:  Donna M Evon; Hannah P Kim; Angela Edwards; Jessica Carda-Auten; Bryce B Reeve; Carol E Golin; Michael W Fried
Journal:  Dig Dis Sci       Date:  2021-02-02       Impact factor: 3.199

5.  Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.

Authors:  Donna M Evon; Souvik Sarkar; Jipcy Amador; Anna S Lok; Richard K Sterling; Paul W Stewart; Bryce B Reeve; Marina Serper; Nancy Reau; K Rajender Reddy; Adrian M Di Bisceglie; David R Nelson; Carol E Golin; Joseph K Lim; Michael W Fried
Journal:  J Hepatol       Date:  2019-05-13       Impact factor: 30.083

6.  Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Authors:  Suzanne Kafaja; Philip J Clements; Holly Wilhalme; Chi-Hong Tseng; Daniel E Furst; Grace Hyun Kim; Jonathan Goldin; Elizabeth R Volkmann; Michael D Roth; Donald P Tashkin; Dinesh Khanna
Journal:  Am J Respir Crit Care Med       Date:  2017-11-03       Impact factor: 30.528

7.  Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Matthew W Roché; Rebecca E Ready; Joel S Perlmutter; Kelvin L Chou; Stacey K Barton; Michael K McCormack; Julie C Stout; David Cella; Jennifer A Miner; Jane S Paulsen
Journal:  Qual Life Res       Date:  2020-08-19       Impact factor: 4.147

8.  Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.

Authors:  Marina Serper; Donna M Evon; Jipcy Amador; Paul W Stewart; Souvik Sarkar; Anna S Lok; Richard K Sterling; Bryce B Reeve; Carol E Golin; K Rajender Reddy; Joseph K Lim; Nancy Reau; David R Nelson; Adrian M Di Bisceglie; Michael W Fried
Journal:  Liver Int       Date:  2021-01-22       Impact factor: 5.828

9.  Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures.

Authors:  Hannah P Kim; Angela Edwards; Bryce B Reeve; Carol E Golin; Donna M Evon
Journal:  J Viral Hepat       Date:  2021-07-17       Impact factor: 3.517

10.  Racial differences in user experiences and perceived value of electronic symptom monitoring in a cohort of black and white bladder and prostate cancer patients.

Authors:  Cleo A Samuel; Angela B Smith; Wendi Elkins; Jennifer Richmond; Zahra Mahbooba; Ethan Basch; Antonia V Bennett; Arlene E Chung; Mattias Jonsson; Ronald C Chen; Bryce B Reeve
Journal:  Qual Life Res       Date:  2020-02-28       Impact factor: 3.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.